NovaBridge Biosciences (NBP) Gains from Sales and Divestitures (2020 - 2022)
NovaBridge Biosciences (NBP) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $160230.6 as the latest value for Q4 2022.
- Quarterly Gains from Sales and Divestitures fell 74.69% to $160230.6 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $160230.6 through Dec 2022, down 74.69% year-over-year, with the annual reading at $160230.6 for FY2022, 74.69% down from the prior year.
- Gains from Sales and Divestitures for Q4 2022 was $160230.6 at NovaBridge Biosciences, down from $633146.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $633146.0 in Q4 2021, with the low at $85284.9 in Q4 2020.
- Average Gains from Sales and Divestitures over 3 years is $292887.2, with a median of $160230.6 recorded in 2022.
- The sharpest move saw Gains from Sales and Divestitures soared 642.39% in 2021, then tumbled 74.69% in 2022.
- Over 3 years, Gains from Sales and Divestitures stood at $85284.9 in 2020, then skyrocketed by 642.39% to $633146.0 in 2021, then plummeted by 74.69% to $160230.6 in 2022.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $160230.6, $633146.0, and $85284.9 for Q4 2022, Q4 2021, and Q4 2020 respectively.